Study

Longitudinal therapy monitoring of ALK-positive non-small cell lung cancer (copy number, cell-free DNA)

Study ID Alternative Stable ID Type
EGAS00001004276 Other

Study Description

Clinical courses of non-small cell lung cancer patients with ALK rearrangements (ALK+ NSCLC) vary widely. We analyzed 271 longitudinal plasma samples from 73 patients with advanced ALK+ NSCLC treated with ALK tyrosine kinase inhibitors by combined hybrid-capture-based targeted sequencing (average 4,100x coverage) for mutation analysis and shallow whole genome sequencing (0.5x coverage) for global copy number profiling from cfDNA.

Study Datasets 2 datasets.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001006297
270 samples with ALK-positiv non-small cell lung cancer, targeted sequencing (198 kb panel size)
270
EGAD00001006298
268 samples with ALK-positiv non-small cell lung cancer, ultra-low coverage whole genome sequencing
268

Who archives the data?

Publications

Citations

Retrieving...
Retrieving...